Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase NA 3Phase 3 3Phase 1/2 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Melanoma 19Triple Negative Breast Neoplasms 14Stomach Neoplasms 13Breast Neoplasms 13Neoplasm Metastasis 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Neoplasms 9Carcinoma 9Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Esophageal Neoplasms 4Cholangiocarcinoma 4Thoracic Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lung Diseases 3

Interventions

Dacarbazine 4pembrolizumab 3binimetinib 3Nivolumab 3encorafenib 2cemiplimab 2Sirolimus 2Ipilimumab 2vitespin 1trametinib 1tilsotolimod 1spartalizumab 1oblimersen 1linrodostat 1lifileucel 1gp100 Melanoma Antigen 1dabrafenib 1bempegaldesleukin 1aldesleukin 1Vinblastine 1Vemurafenib 1Tretinoin 1Tacrolimus 1Standard of Care 1Sodium Chloride 1Radiotherapy 1Radiation 1Interleukin-2 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Skin Neoplasms × pembrolizumab × Clear all
NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Iovance Biotherapeutics, Inc.

Phase 3 Recruiting
670 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
1,564 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡